MedTrace Logo

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

NCT05876065 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2025-09-11

No results posted yet for this study

Summary

To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.

Conditions

Interventions

DRUG

XC

Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days

DRUG

TPC

Any physician's choice as maintenance therapy (except for XC regimen)

Sponsors & Collaborators

  • Wenjin Yin

    lead OTHER

Principal Investigators

  • Wenjin Yin, M.D. · Renji Hospital,School of Medicine, Shanghai Jiaotong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2026-06-30
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05876065 on ClinicalTrials.gov